Partnership advances liver cancer treatment
Scientist Live, 12 May 2025
Oops! Your browser version is not supported by our website.
Please use these following browsers to view this page:
Scientist Live, 12 May 2025
Safety First, Quality Always: We are continuously improving the safety of our operations with the patient’s safety in mind.
Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea.
Hovione today announced the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive Officer, effective 1st April 2022
Investment in Hovione Tejo will expand industrial capacity and strengthen the company’s global leadership in spray drying and other advanced pharmaceutical manufacturing technologies.
BCSD Portugal, 23 July 2021
C&EN, November 12, 2018